Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Dec 23, 2024
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said
https://www.marketwatch.com/story/novo-nordisks-27-drop-was-market-overreaction-analysts-say-fabe03c6?mod=mw_rss_topstories
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service